BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome

 
• By Alaric DeArment
BMS announced data from the Phase III COMMANDS trial of Reblozyl • Source: Shutterstock

More from Clinical Trials

More from R&D